Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for philadelphia chromosome-positive acute lymphoblastic leukemia

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 4, 2012, Pages 652-654

  Caocci, Giovanni ^a   Vacca, Adriana ^a   Ledda, Antonio ^a   Murgia, Francesca ^a   Piras, Eugenia ^a   Greco, Marianna ^a   Arras, Marcella ^a   Atzeni, Sandra ^a   Littera, Roberto ^a   La Nasa, Giorgio ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; BCR ABL PROTEIN; BOSUTINIB; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DASATINIB; DAUNORUBICIN; DOXORUBICIN; FLUDARABINE; IMATINIB; MELPHALAN; MESSENGER RNA; METHOTREXATE; MITOXANTRONE; NILOTINIB; THIOTEPA; TREOSULFAN; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE MUTATION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPHYLAXIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PHILADELPHIA CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECURRENCE; REMISSION INDUCTION; THIAZOLES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84858072046     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.12.587     Document Type: Letter

References (12)

1. Vignetti M., Fazi P., Cimino G., et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood 2007, 109:3676-3678.
2. +) acute lymphoblastic leukemia. Blood 2010, 116:2070-2077.
3. Foà R., Vitale A., Vignetti M., et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2011, 118:6521-6528.
4. Lee H.J., Thompson J.E., Wang E.S., et al. Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer 2011, 117:1583-1594.
5. Lee K.H., Lee J.H., Choi S.J., et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2005, 19:1509-1516.
6. Mathisen M.S., O'Brien S., Thomas D., et al. Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Hematol Malig Rep 2011, 6:187-194.
7. Anderlini P., Sheth S., Hicks K., et al. Re: imatinib mesylate administration in the first 100 days after stem cell transplantation. Biol Blood Marrow Transplant 2004, 10:883-884.
8. Ribera J.M., Oriol A., González M., et al. Programa Español de Tratamiento en Hematología; Grupo Español de Trasplante Hemopoyético. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: final results of the CSTIBES02 trial. Haematologica 2010, 95:87-95.
9. Wassmann B., Pfeifer H., Stadler M., et al. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2005, 106:458-463.
10. Kebriaei P., Saliba R., Rondon G., et al. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant 2011, e-pub ahead of print August 23, 2011; doi: 10.1016/j.bbmt.2011.08.011.
11. O'Hare T., Walters D.K., Stoffregen E.P., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65:4500-4505.
12. Walz C., Sattler M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Critic Rev Oncol Hematol 2006, 57:145-164.